"Research must be at the center of Italy's economic growth," stated Mario Draghi. Italy risks losing the train of innovation in the biomedical field as a result of bureaucracy, a lack of funding and personnel, and privacy regulations that make data management nearly impossible. The country is also desperately attempting to recover from delays in implementing the 2014 European Regulation on clinical trials. In this sense, the pharmaceutical industry alone is worth a trillion dollars, and major corporations have plans to invest that much between now and 2025. A dish from which, under these circumstances, Italy risks receiving only crumbs. To take stock of the clinical trials are the experts gathered in the conference on "Clinical research in Italy", organized in Rome, at the headquarters of the ISS, by Fadoi, the Scientific Society of internists hospital doctors, who took over 70% of Covid patients during the pandemic. The conference, streamed live on YouTube and attended by representatives of institutions, research institutes, general and health directorates of hospitals, scientific associations, industry, and contract research organizations, demonstrates that the past two and a half years of Covid have taught us how crucial it is for the public and private sectors to collaborate on clinical research. In Italy, however, non-profit clinical trials decreased by 51% between 2009 and 2019. Italy's participation in clinical trials was and continues to be hindered by excessively lengthy bureaucratic processes. To put it simply, if our country has 4.6 per 10,000 inhabitants per year, Germany has 5.6, Spain and France have 6, Great Britain has 6.8, and Holland has 16.7, not to mention the Danish record of 25.5.